Bio-effect model applied to (131)I radioimmunotherapy of refractory non-Hodgkin’s lymphoma

PURPOSE: Improved data collection methods have improved absorbed dose estimation by tracking activity distributions and tumor extent at multiple time points, allowing individualized absorbed dose estimation. Treatment with tositumomab and (131)I-tositumomab anti-CD20 radioimmunotherapy (BEXXAR) yiel...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Roberson, Peter L., Amro, Hanan, Wilderman, Scott J., Avram, Anca M., Kaminski, Mark S., Schipper, Matthew J., Dewaraja, Yuni K.
Formato: Artigo
Idioma:Inglês
Publicado: 2010
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3312018/
https://ncbi.nlm.nih.gov/pubmed/21174088
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-010-1699-3
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares